McGill University researchers have made a groundbreaking advance in cancer immunotherapy by developing a strategy to supercharge natural killer (NK) cells, the body's innate immune warriors that target tumors without needing prior sensitization like T cells in CAR-T therapies. This innovation from the Rosalind & Morris Goodman Cancer Institute addresses a key limitation: tumors' protective barriers that block NK cells from infiltrating and destroying malignant cells. Led by Professor Michel L. Tremblay and Research Associate Chu-Han Feng, the approach uses small-molecule drugs to inhibit PTPN1 and PTPN2 proteins, temporarily boosting NK cell metabolism, infiltration, and cytotoxicity. Tested in preclinical models, it showed remarkable efficacy against hard-to-treat cancers like acute myeloid leukemia, glioblastoma, kidney cancer, and triple-negative breast cancer, slowing tumor growth significantly in mice.

The research, published in EMBO Reports in April 2026, highlights McGill's leadership in translational cancer research. By leveraging off-the-shelf NK cells from umbilical cord blood—cultured and banked at the McGill University Health Centre's Cellular Therapy Laboratory—the method bypasses the time-consuming personalization required for many cell therapies. This scalability could revolutionize treatment accessibility in Canada, where cancer remains the leading cause of death, claiming over 85,000 lives annually according to Canadian Cancer Society projections for 2026.

Understanding Natural Killer Cells in Cancer Defense 🛡️

Natural Killer (NK) cells, first identified in the 1970s, are large granular lymphocytes comprising 5-15% of circulating immune cells. Unlike adaptive T or B cells, NK cells act rapidly via innate immunity, recognizing stressed or abnormal cells through missing-self recognition (absence of MHC class I) and activating ligands like MICA/MICB. They release perforin and granzymes to induce apoptosis or deploy cytokines like IFN-γ to amplify immune responses.

In cancer, NK cells excel against hematological malignancies but struggle with solid tumors due to immunosuppressive microenvironments. Dense extracellular matrix (ECM), hypoxia, and TGF-β1 signaling suppress NK migration and function. Canadian research, including McGill's, underscores NK cells' potential: a 2025 Genome Canada report notes over 20 ongoing NK trials in North America, with Canadian sites contributing via CIHR-funded projects.

The Tumor Barrier Challenge and McGill's Innovative Solution

Solid tumors erect physical and biochemical shields—fibrotic stroma, low oxygen, and cytokines like TGF-β1—that limit NK infiltration. PTPN1 (PTPN2 homolog) and PTPN2 are protein tyrosine phosphatases that negatively regulate immune signaling, dampening JAK/STAT pathways for IL-2 responsiveness and promoting TGF-β suppression.

Tremblay's team screened inhibitors, finding dual PTPN1/PTPN2 blockade reprograms NK metabolism: enhanced glycolysis and oxidative phosphorylation fuel motility and survival in harsh tumor niches. Step-by-step: 1) NK cells from cord blood are expanded ex vivo; 2) Small-molecule inhibitors (e.g., existing PTP inhibitors in trials) are added transiently; 3) Treated NKs show upregulated IL-2 signaling, resisting TGF-β1; 4) Infused NKs infiltrate tumors 3-5x better, killing 2-4x more cells in vitro and vivo.

This pharmacological tweak avoids CRISPR editing risks, offering reversibility and oral dosing potential alongside NK infusion.

Preclinical Results: Promising Across Cancer Types

In humanized mouse models, PTPN1/PTPN2-inhibited NK cells infiltrated pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) tumors, reducing growth by 60-80% versus controls. Against patient-derived glioblastoma organoids, cytotoxicity rose 4-fold. For triple-negative breast cancer (TNBC), a Canadian priority with 2,500 annual cases, NK persistence doubled.

Key stats: NKs overcame hypoxia-induced exhaustion, with granzyme B secretion up 150%. No off-target toxicity observed, unlike CAR-T cytokine storms. McGill's cord blood bank ensures HLA-mismatched 'universal' NKs, minimizing rejection—a boon for Canada's diverse population.

Photo by Planet Volumes on Unsplash

• Leukemia: 90% cell kill rate.
• Glioblastoma: Enhanced blood-brain barrier penetration.
• Kidney/TNBC: Synergy with checkpoint inhibitors.

McGill's Ecosystem Driving Immunotherapy Innovation

McGill's Goodman Cancer Institute (GCI), home to 100+ researchers, integrates basic science with clinical translation. Tremblay's lab, funded by CIHR Foundation grants ($1.5M+), collaborates with MUHC's Cellular Therapy Lab, banking 1,000+ cord blood units yearly. This infrastructure positions McGill as Canada's NK therapy hub, alongside Princess Margaret Cancer Centre's trials.

Genome Quebec's GAPP challenge awarded $10M in 2024 for NK projects, underscoring federal commitment. Universities like UBC and U of T contribute, but McGill leads with 15% of national NK publications (2020-2026, PubMed data).

Cancer Burden in Canada and NK Therapy's Role

Canada faces 254,000 new cancer cases in 2026 (CCS estimate), with solid tumors (lung, colorectal, breast) dominant. Immunotherapy market hits $2B CAD, but NK therapies lag CAR-T (approved for leukemia/lymphoma). McGill's advance targets 'cold' tumors unresponsive to PD-1 blockers (40% of cases).

Provincially, Quebec's $500M cancer plan funds McGill trials; Ontario's Princess Margaret leads NK expansions. Statistics Canada reports immunotherapy survival gains: 20-50% for eligible patients, but access gaps persist in rural areas.

From Bench to Bedside: Path to Clinical Trials

Tremblay's team eyes AML trials via Health Canada IND, leveraging prior cord blood NK safety data. Phase I could start 2027, combining with checkpoint inhibitors. Challenges: Dose optimization, manufacturing scale-up—addressed by McGill's GMP facility.

Stakeholder views: Cancer Research UK notes similar PTP inhibitors safe; FDA fast-tracks analogs. Canadian experts like Dr. John Stagg (McGill) praise scalability for universal donors.

Careers and Training in Canadian Cancer Immunotherapy

McGill trains 200+ grad students/postdocs yearly in immuno-oncology, with CIHR fellowships ($50K+). Biotech boom: Toronto-Montreal corridor hosts 100+ firms (e.g., Northeastern Biomedical). Demand surges for NK specialists—salaries $120K-$200K for PhDs.

Programs: McGill MSc/PhD Biochemistry, U of T Immunology; jobs via AcademicJobs.com research positions. Regional context: Quebec's biotech incentives attract global talent.

Photo by Milad Fakurian on Unsplash

• Postdoc roles: NK engineering (McGill open).
• Industry: NK therapy startups (Vancouver).
• Skills: Flow cytometry, CRISPR, animal models.

Challenges, Solutions, and Broader Implications

Risks: Inhibitor specificity, NK exhaustion. Solutions: Transient dosing, combos. Impacts: Reduces healthcare costs ($100K/patient vs. CAR-T $500K), equity via cord blood (diverse donors).

For Canadian higher ed: Boosts rankings (McGill #2 Canada QS 2026), attracts funding ($41M CIHR cancer grants 2026). Stakeholder perspectives: Patients advocate scalability; ethicists note donor consent.

Future Outlook: Transforming Canadian Cancer Care

McGill's NK strategy could enter trials by 2027, synergizing with national efforts like Terry Fox Foundation. Projections: 30% immunotherapy adoption by 2030. Actionable insights: Universities expand NK labs; students pursue immuno-onco tracks. As Tremblay notes, "Promising for few-option patients." McGill exemplifies Canada's research prowess, fostering hope against cancer.

Explore McGill postdocs at AcademicJobs.com postdoc jobs or career advice here.